^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/09/2022
    Excerpt:
    TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...Alveolar Soft Part Sarcoma (ASPS)...for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/13/2023
    Excerpt:
    Alveolar Soft Part Sarcoma (ASPS),category 2A recommendation, Preferred regimen:...Atezolizumab